Is Sjogren’s a Form of Lupus? Key Differences & Overlap

Sjögren’s syndrome is not a form of lupus. They are classified as two separate systemic autoimmune diseases, each with its own diagnostic criteria and characteristic patterns of organ damage. The confusion is understandable, though, because the two conditions share a striking number of genetic susceptibility genes, circulating antibodies, and even symptoms, and they co-occur in the same person often enough to blur the line at the bedside.

Why the Two Get Confused

Sjögren’s syndrome is best known for attacking moisture-producing glands, causing severe dry eyes and dry mouth. Lupus, or systemic lupus erythematosus (SLE), is best known for widespread inflammation that can hit the skin, joints, kidneys, and brain. On paper, those sound easy to tell apart. In practice, Sjögren’s can also cause joint pain, fatigue, rashes, and kidney problems. Lupus can also cause dry eyes and dry mouth. Both diseases disproportionately affect women, both tend to produce antinuclear antibodies (ANA), and both can involve many of the same organ systems. A patient sitting in a rheumatologist’s office with fatigue, joint pain, a positive ANA, and dry eyes could plausibly be on a path toward either diagnosis, or both.

The overlap is not just clinical coincidence. At the molecular level, SLE and Sjögren’s share a significant number of susceptibility genes and clinical features, making them two of the most closely related autoimmune diseases in rheumatology.¹ Researchers studying gene expression patterns in both diseases found that their shared genes cluster around the type I interferon signaling pathway and antiviral defense mechanisms, suggesting the two conditions tap into some of the same immune misfiring at a fundamental level.²

When Both Conditions Appear Together

One of the biggest sources of confusion is that Sjögren’s syndrome frequently develops in people who already have lupus. This is sometimes called “secondary Sjögren’s syndrome,” though many specialists now prefer terms like “associated” or “overlapping” Sjögren’s, since “secondary” can give the misleading impression that the condition is less real or less important.³ Regardless of the label, the overlap is common. Meta-analyses put the prevalence of Sjögren’s among lupus patients at roughly 14 to 18 percent, though individual studies using newer classification criteria have reported rates as high as 35 percent.⁴⁵

The wide range in those estimates partly depends on which diagnostic criteria are applied. Older criteria required a positive lip biopsy or certain antibody combinations; newer criteria weight different features and tend to capture more cases. One study applied both the older 2002 criteria and the newer 2016 criteria to the same group of lupus patients and found that the Sjögren’s prevalence jumped from 23 percent to 35 percent just by switching the classification system.⁵ That kind of swing tells you how much the diagnostic boundary between these diseases is shaped by the criteria we choose rather than by a crisp biological dividing line.

How the Two Conditions Actually Differ

Despite the overlap, lupus and Sjögren’s have genuinely different tendencies that matter for prognosis and treatment. A large cohort study of lupus patients found that those who also had Sjögren’s formed a distinct subgroup: they were more likely to be older, white, and female, and they had higher rates of photosensitivity, oral ulcers, and Raynaud’s phenomenon. At the same time, they had lower rates of kidney disease, which is one of the most feared complications of lupus.⁶

Kidney involvement illustrates the difference well. In lupus, kidney damage typically involves immune-complex deposition in the glomeruli, the tiny filtering units of the kidney, and can lead to serious glomerulonephritis. In primary Sjögren’s, when the kidney is affected at all, the more common pattern is inflammation of the tubules, the structures that handle reabsorption, rather than the glomeruli.⁷ The distinction matters because tubular disease tends to cause problems like kidney stones and difficulty concentrating urine, whereas glomerular disease can cause protein loss in the urine and progressive kidney failure. Different mechanisms, different monitoring, different urgency.

Even in tissues where both diseases cause inflammation, they leave different fingerprints. A study comparing salivary gland biopsies from Sjögren’s and lupus patients found that Sjögren’s produced moderate to intense inflammation with destruction of salivary ducts, while lupus caused milder inflammation with thickening and scarring of the duct walls. The antibody deposits differed too: Sjögren’s patients tended to show IgA deposits between duct cells, while lupus patients showed IgG deposits along the basement membrane.⁸ Both diseases can cause dry mouth, but by slightly different routes.

The Antibody Picture

Blood tests are one of the main tools rheumatologists use to sort out these diagnoses, and this is where things get especially tangled. Both diseases commonly produce ANA. Both can produce anti-Ro (also called SSA) and anti-La (SSB) antibodies. Anti-Ro and anti-La are strongly associated with Sjögren’s, but they also appear in a substantial fraction of lupus patients, especially those with photosensitive rashes and those who go on to develop secondary Sjögren’s.

Anti-double-stranded DNA (anti-dsDNA) antibodies have traditionally been considered a hallmark of lupus and are used to track disease activity. But they can also appear in primary Sjögren’s patients who do not meet criteria for lupus, which complicates the picture. A recent review highlighted that the presence of anti-dsDNA in primary Sjögren’s can blur the diagnostic boundary between the two conditions.⁹ Conversely, the same large cohort study mentioned above found that lupus patients who also had Sjögren’s were less likely to carry anti-dsDNA antibodies and more likely to carry anti-Ro and anti-La antibodies compared to lupus patients without Sjögren’s.⁶

In practical terms, no single antibody test reliably separates the two diseases. Diagnosis depends on the full clinical picture: the pattern of symptoms, the combination of antibodies, gland function tests, and sometimes biopsy results. A rheumatologist assembles these pieces together rather than relying on any one marker.

A Risk Unique to Sjögren’s

One of the starkest differences between the two conditions is lymphoma risk. People with primary Sjögren’s syndrome have a substantially elevated risk of developing non-Hodgkin lymphoma, particularly a type called MALT lymphoma that arises in the mucous membranes. This risk does not apply to lupus in the same way. The lymphomas in Sjögren’s tend to be B-cell tumors, and several clinical and laboratory features present at the time of Sjögren’s diagnosis can independently predict future lymphoma development.¹⁰ Persistent salivary gland swelling, low complement levels, and certain patterns of cryoglobulinemia are among the warning signs rheumatologists watch for. This lymphoma surveillance aspect of care is a significant part of managing Sjögren’s that has no real parallel in lupus management.

Treatment Overlap and Where It Diverges

One reason people sometimes think Sjögren’s and lupus are versions of the same disease is that they share some of the same treatments. Hydroxychloroquine, perhaps the best-known drug in lupus care, is also used in Sjögren’s. In lupus, it is considered a foundational treatment that reduces mortality and prevents organ damage. In Sjögren’s, it is frequently used for joint pain, fatigue, and skin symptoms, and it is considered one of the primary systemic treatments, particularly early in the disease course.¹¹¹²

But the shared use of hydroxychloroquine masks an important difference: lupus has a much wider toolkit of proven systemic therapies, including belimumab (a B-cell targeting biologic approved for lupus), mycophenolate, azathioprine, and calcineurin inhibitors for kidney disease. Sjögren’s has historically had far fewer disease-modifying options, especially for the hallmark dryness symptoms that dominate daily life. Much of Sjögren’s care still centers on managing symptoms rather than modifying the disease itself.

For dry mouth specifically, medications called secretagogues, which stimulate whatever salivary gland function remains, are a mainstay. Cevimeline and pilocarpine work by activating receptors on salivary gland cells to increase saliva production and improve the subjective sensation of oral dryness.¹³ These drugs have no role in lupus treatment, because lupus-related dry mouth, when it occurs, is usually milder and driven by a different mechanism.

The biologic therapy landscape for Sjögren’s is evolving. A phase II trial tested the combination of belimumab (already approved for lupus) and rituximab (a B-cell depleting drug used off-label in both diseases) sequentially in primary Sjögren’s patients. The combination achieved greater and more sustained depletion of B cells in both blood and salivary glands, and disease activity scores dropped substantially more than with placebo.¹⁴ While this is still early-phase data, it represents one of the more promising avenues for actually modifying the disease process in Sjögren’s rather than just managing symptoms.

Pregnancy Concerns With Either Diagnosis

Both Sjögren’s and lupus can carry specific risks during pregnancy, and the overlap centers on anti-Ro/SSA and anti-La/SSB antibodies. These antibodies can cross the placenta and affect the developing fetal heart, potentially causing congenital heart block, a condition where the electrical signals that coordinate heartbeats are disrupted. The risk is present in any pregnancy where the mother carries these antibodies, whether the underlying diagnosis is Sjögren’s, lupus, or both.¹⁵ This is one area where having either diagnosis prompts the same kind of monitoring: serial fetal echocardiograms to watch for early signs of heart block, typically between weeks 16 and 26 of pregnancy. The risk is relatively low in absolute terms, but the consequences can be serious enough that monitoring is standard for antibody-positive women regardless of which autoimmune diagnosis they carry.

What Their Gut Bacteria Have in Common, and What They Don’t

An interesting thread of research has looked at the microbiome in both diseases. A study comparing primary Sjögren’s patients, lupus patients, and healthy controls found that both patient groups had similar shifts in their gut bacteria that set them apart from healthy people. The implication is that some shared disruption in gut microbial communities may be part of the common autoimmune terrain the two diseases occupy. But when researchers looked at oral bacteria, the picture diverged: the oral microbiome showed disease-specific differences between Sjögren’s and lupus patients.¹⁶ That finding fits with what you might expect. Sjögren’s directly attacks the salivary glands, changing the composition and flow of saliva, which is one of the major forces shaping the oral ecosystem. Lupus, by contrast, does not directly destroy salivary tissue in the same way, so the oral environment is less disrupted.

When Children Are Affected

Both diseases can appear in children and adolescents, though each follows a somewhat different pattern in younger patients compared to adults. Juvenile lupus tends to present more aggressively than adult-onset lupus, with a higher frequency of kidney and neurological involvement. Juvenile Sjögren’s syndrome is rarer and can be harder to recognize, partly because children may not articulate dryness symptoms the way adults do, and partly because clinicians may not think of it in a young patient. The antibody profiles also differ slightly by disease: anti-double-stranded DNA is characteristic of juvenile lupus, while anti-Ro (SSA) and anti-La (SSB) antibodies alongside ANA are more typical of juvenile Sjögren’s.¹⁷ Pediatric rheumatologists must navigate the same diagnostic ambiguity as their adult counterparts, but with even fewer clinical trials to guide treatment decisions in younger populations.

Getting the Diagnosis Right Matters

Treating Sjögren’s as though it were just a mild variant of lupus, or vice versa, leads to problems. If a doctor thinks of a patient’s Sjögren’s symptoms as a footnote to lupus, they may not pursue adequate dryness management, potentially leading to severe dental decay (a serious and common consequence of chronic dry mouth), corneal damage, or salivary gland infections. Similarly, if a patient with evolving lupus is told they “just” have Sjögren’s, kidney involvement or other serious organ manifestations could be undermonitored.

The practical upshot for patients: if you have been diagnosed with one of these conditions and develop symptoms that feel like they belong to the other, raise it with your rheumatologist. The overlap is common enough that good clinicians expect it, and catching associated Sjögren’s in a lupus patient or recognizing emerging lupus features in a Sjögren’s patient changes the monitoring and treatment plan in meaningful ways. These are two distinct diseases that happen to be neighbors. Knowing where one ends and the other begins, to the extent that biology cooperates with clean boundaries, makes a real difference in how well each one is managed.